PerClot Polysaccharide Hemostatic System
Baxter Healthcare Corporation · Decision date Jun 8, 2026
What did the FDA approve?
FDA records P210036/S007 as a supplement to PMA P210036, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jun 8, 2026.
FDA approval order statement
Approval for the transfer of production of the PerClot Absorbable Hemostatic Powder to an alternate manufacturing site, Beijing Huan Qiu Li Kang Biotech Co., Ltd., (HQLK) in Beijing, China.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Jun 8, 2026
- FDA change category
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P210036/S007
- Regulatory pathway
- PMA supplement
- Applicant
- Baxter Healthcare Corporation
- Product code
- LMG
- Decision code
- APPR
- Decision date
- Jun 8, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, absorbable hemostatic, non-collagen based.
- Applicant
- Baxter Healthcare Corporation
- Product code
- LMG
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P210036. Subsequent supplements may change the device or its indications.
FDA decision timeline
P210036 · Original PMA
PerClot Polysaccharide Hemostatic System
P210036/S007 received
Application receipt date recorded by FDA.
P210036/S007 · FDA decision
Normal 180 Day Track No User Fee
P210036/S008 · Related supplement
PerClot Polysaccharide Hemostatic System
P210036/S009 · Related supplement
PerClot Polysaccharide Hemostatic System
P210036/S010 · Related supplement
PerClot Absorbable Hemostatic Powder Accessory Tips
Timeline entries are records held by MedtechLedger for P210036. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210036
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Baxter Healthcare Corporation | PMA approval | May 19, 2023 | FDA | |
PerClot Polysaccharide Hemostatic SystemP210036/S008 | Baxter Healthcare Corporation | PMA supplement | Aug 7, 2026 | FDA |
PerClot Polysaccharide Hemostatic SystemP210036/S009 | Baxter Healthcare Corporation | PMA supplement | Aug 7, 2026 | FDA |
| Baxter Healthcare Corporation | PMA supplement | Nov 7, 2026 | FDA |
Explore the linked device profile
Other records with product code LMG
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SURGICEL Absorbable HemostatsN12159/S132 | ETHICON, Inc. | PMA supplement | Nov 5, 2026 | FDA |
| ETHICON, Inc. | PMA supplement | Jul 28, 2026 | FDA | |
Arista AHP050038/S044 | Davol, Inc. | PMA supplement | Jul 15, 2026 | FDA |
SURGICEL Absorbable HemostatsN12159/S130 | ETHICON, Inc. | PMA supplement | Jun 25, 2026 | FDA |
Arista AHP050038/S043 | Davol, Inc. | PMA supplement | Apr 29, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Baxter Healthcare Corporation
- Headquarters
- Not reported
- Brand website
- baxter.com
- FDA applicant address
- 25212 W. Illinois Rte. 120, Round Lake, IL, 60073
Sources and methodology
- Original FDA record: P210036/S007
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

